IndraLab

Statements

APS binds CALM1. 9 / 9
| 9
sparser
"People with type 1 diabetes using four different AID systems [Minimed™780G (MM780G), Accu-Chek® Insight-Diabeloop (DBLG), Tandem-Control-IQ, and Ypsopump Cambridge HCL-app (Cam-APS)] were included in the study."
40666106
sparser
"174 patients (60: MM780G, 45: DBLG, 30: Control-IQ, 39: Cam-APS), aged 18–73, predominantly women, were enrolled."
40666106
sparser
"Among the 174 participants in the study, 4 different systems were used: 60 with MM780G, 45 with DBLG, 30 with Control-IQ and 39 with Cam-APS."
40666106
sparser
"Specifically, the use of previous insulin pump was significantly higher (87%) in MM780G-group and lower (59%) in CAM-APS group and DLBG system users had significantly longer duration of diabetes than the other groups."
40666106
sparser
"After three months, 50% of MM780G and Cam-APS users, as well as approximately 40% of Control-IQ and DBLG users, had achieved the goal."
40666106
sparser
"Our sample shows a similar phenomenon, with a significant increase in TIR after 12 months of the implementation of an AID system, which is achieved at 3 months, regardless of the system used, with the exception of the Cam-APS system where TIR values decrease from the first 3 months to 1 year."
40666106
sparser
"In contrast, although 50% of patients in the Cam-APS group achieved the target at three months, only 28.7% maintained this control at 1 year."
40666106
sparser
"To enhance clinical applicability and interpretation, our meta-analysis incorporated focused subgroup analyses of two prominent HCL systems extensively studied in individual trials: the Cam-APS FX Closed-Loop system and the Medtronic MiniMed 670G HCL system."
40547532
sparser
"Interestingly, despite the Cam-APS FX being the only licensed system to utilize ultra-rapid-acting insulin (URAI) analogs ( xref ), our analysis uncovered a lack of substantial glycemic improvement coupled with a higher frequency of adverse events when using URAI analogs with this system."
40547532